Advertisement

Advertisement

IASLC World Conference on Lung Cancer 2022

Lung Cancer

Exploratory Analysis of POSEIDON: Chemoimmunotherapy Regimen May Offer Survival Benefit in Subgroups of Metastatic NSCLC

The addition of the CTLA-4 inhibitor tremelimumab to durvalumab and chemotherapy in the first-line setting has already demonstrated an overall survival and progression-free survival benefit vs chemoth...

Lung Cancer

NELSON vs NLST: Nodule Management Based on Volumetry Shows Increased Benefits

Lung cancer screening has been shown to significantly reduce lung cancer mortality, but some management protocols have more benefit than others, according to data presented at the International Associ...

Lung Cancer

IMpower010: Early Survival Data Favor Atezolizumab Over Best Supportive Care in Resected NSCLC With PD-L1 Expression ≥ 50%

Early results from the IMpower010 trial showed an overall survival trend favoring adjuvant atezolizumab vs best supportive care for patients with PD-L1–positive (tumor expression ≥ 1%), stage II–IIIA ...

Lung Cancer

NADIM Trial: Neoadjuvant Chemoimmunotherapy Improved Survival in Resectable, Stage IIIA NSCLC

In patients with resectable, stage IIIA non–small cell lung cancer (NSCLC), the addition of neoadjuvant nivolumab to platinum-based chemotherapy significantly improved overall survival compared with n...

Lung Cancer
Immunotherapy

Real-World Experience With Durvalumab at the Mayo Clinic Mirrors PACIFIC Findings

Concurrent chemoradiation followed by durvalumab has become the standard of care in patients with unresectable, locally advanced non–small cell lung cancer (NSCLC), based on the PACIFIC trial.1 But cl...

Lung Cancer

National Lung Screening Trial Results Highlight Importance of Lifelong Follow-up

Approximately 6% of patients with stage I to III lung cancer develop a second primary lung cancer within 5 years of their initial diagnosis, according to research presented at the International Associ...

Lung Cancer

High-Intensity Intervention Helps One-Third of Participants in Lung Cancer Screening Program Quit Smoking

Despite significant advancements in cancer therapy, a primary means to avoid lung cancer is prevention, and smoking cessation is the most basic intervention. Unfortunately, for long-term smokers, that...

Lung Cancer
Immunotherapy

DART Trial: Concurrent Radiotherapy Plus Durvalumab Active in Older Patients With Locally Advanced Lung Cancer

Interim results of a phase II study have demonstrated the safety and feasibility of treating elderly and frail patients with locally advanced non–small cell lung cancer (NSCLC) with the monoclonal ant...

Lung Cancer
Immunotherapy

Real-World Evidence Confirms Survival Benefit of Durvalumab in Locally Advanced Non–Small Cell Lung Cancer

In locally advanced non–small cell lung cancer (NSCLC), immunotherapy consolidation with the PD-L1 inhibitor durvalumab improved overall survival in the PACIFIC trial,1 thus leading to its use after c...

Lung Cancer
Immunotherapy

Sugemalimab Found to Be a Safe and Effective Consolidation Therapy for Patients With Unresectable Stage III NSCLC

The human monoclonal antibody sugemalimab is a safe and effective consolidation therapy for patients with unresectable stage III non–small cell lung cancer (NSCLC) without disease progression after ei...

Lung Cancer
Supportive Care

Sexual Dysfunction Is Prevalent Among Women With Lung Cancer

Sexual dysfunction is highly prevalent in women with lung cancer, with most participants in a survey reporting little to no interest in sexual activity, according to research led by Narjust Florez (Du...

Lung Cancer

Study Investigates Incidence, Timing, and Survival of Patients With Second Primary Lung Cancer

Using data from the National Lung Screening Trial (NLST), researchers found that the incidence of second primary lung cancer was approximately 4% among the entire cohort of patients with lung cancer a...

Lung Cancer

NELSON Trial Protocol May Be More Sensitive Than NLST, May Increase Benefits of Lung Cancer Screening

The protocol used to screen and detect lung cancer in the NELSON trial may be more sensitive than the protocol used in the National Lung Cancer Screening Trial (NLST), particularly for early-stage can...

Lung Cancer
Immunotherapy

Durvalumab Plus Concurrent Radiotherapy in Unresectable Locally Advanced NSCLC: DOLPHIN Study

Researchers from Japan recently reported that the first phase II study to evaluate the efficacy and safety of durvalumab and concurrent curative radiation therapy for PD-L1–positive unresectable local...

Lung Cancer

Research Suggests Air Pollution Be Included as Risk Factor for Nonsmoking Patients With Lung Cancer

Researchers from Vancouver, British Columbia examined the effect of duration of past exposure to air pollution with lung cancer diagnosis in new research presented by Myers et al at the International ...

Lung Cancer

Disparities in the Diagnosis of Lung Cancer Among Younger vs Older Adults

Younger patients with lung cancer are significantly more likely than older patients to be diagnosed with later stages of disease, illustrating the need to develop strategies to increase the early dete...

Lung Cancer

Increased Utilization of SBRT Has Decreased Treatment Disparities for Early-Stage NSCLC

The use of stereotactic body radiotherapy (SBRT) for patients with non–small cell lung cancer (NSCLC) can reduce treatment disparities between White and Black patients, according to research presented...

Lung Cancer
Genomics/Genetics
Immunotherapy

Study Finds Adding Tremelimumab and Durvalumab to Chemotherapy Improves Overall Survival in Metastatic NSCLC Regardless of KRAS/STK11/KEAP1 Mutations

Patients with metastatic non–small cell lung cancer (NSCLC) who received a combined therapy of tremelimumab, durvalumab, and chemotherapy experienced longer overall survival compared with those who re...

Advertisement

Advertisement



Advertisement